Saturday, February 6, 2021

Live, Interactive Virtual Conference!

8:00 AM – 4:55 PM EST

The 17th Annual International Symposium on Melanoma and Other Cutaneous Malignancies^® is a single-day educational conference designed to examine current and emerging treatments in melanoma, basal cell carcinoma, squamous cell carcinoma, and other skin-related cancers. This engaging program, with insights from world-renowned experts, will bring you up-to-date on the evolving standards of care in melanoma and other cutaneous malignancies.

The fast-paced and interactive nature of this symposium will provide concise yet thorough updates for physicians who treat skin cancers. With unmatched access to leading international experts in the field, this program will enable participants to apply the latest research to improve their clinical practice. Dynamic and interactive Medical Crossfire^® discussions will allow experts to debate today’s key questions in the field and provide evidence-based answers to attendees to improve their management of patients with melanoma and other cutaneous malignancies.

Physicians' Education Resource^®’s top priority is ensuring the safety and security of our attendees, staff, and operational personnel. We are dedicated to remaining informed about the ongoing COVID-19 pandemic at the global and local levels. As we develop the programming for this activity, Physicians' Education Resource^® will follow the guidelines to optimize health and conditions for attendees during the event. Ongoing updates on Physicians' Education Resource^®'s plans related to this event, including education and programming, will continue to be available at www.gotoper.com/conferences/ime/meetings/17th-annual-international-symposium-on-melanoma-and-other-cutaneous-malignancies. Please note attendance at any public event increases the risk of contracting COVID-19 or other airborne illness, and attendees assume all risk associated with attendance. Any attendees who feel ill, regardless of their symptoms, should not attend this event.

• Interact with top experts in the field of cutaneous malignancies
• Develop action plans to improve the treatment of your patients with skin-related cancers
• Learn the current best practices for managing adverse events of current and novel therapies used to treat melanoma and other cutaneous tumors
• Network with colleagues and peers

Physicians’ Education Resource^®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource^®, LLC designates this live activity for a maximum of 6.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource^®, is approved by the California Board of Registered Nursing, Provider #16669, for 6.5 Contact Hours.

This activity is supported by educational grants from Bristol Myers Squibb, Novartis Pharmaceuticals Corporation,OncoSec Immunotherapies, Inc., Inc., Regeneron Pharmaceuticals, Inc., and Sanofi Genzyme.

This educational activity is directed toward medical oncologists, fellows, surgical oncologists, and radiation oncologists who treat patients with skin and other cutaneous malignancies. Dermatologists, dermatopathologists and pathologists, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of melanoma and other cutaneous malignancies will also be invited to participate.

At the conclusion of this symposium, you should be better prepared to:

• Analyze the use of biomarkers in personalizing care for patients with cutaneous malignancies
• Assess the latest clinical trial on current and emerging treatment options for melanoma and other skin-related tumors
• Develop optimal management protocols for the treatment of melanoma, basal cell carcinoma, squamous cell carcinoma, and other cutaneous malignancies
• Design best practices for the prevention and mitigation of treatment-associated adverse events in the management of cutaneous malignancies

• Emerging potential therapeutic targets for the treatment of melanoma and other cutaneous malignancies
• Best practices for use of BRAF/MEK inhibitors and checkpoint inhibitors in melanoma treatment
• Management strategies for uncommon cutaneous malignancies

Omid Hamid, MD
Chief, Translational Research and Immuno-Oncology
Director, Cutaneous Malignancies
The Angeles Clinic and Research Institute, an affiliate of Cedars Sinai
Director of Experimental Therapeutics
Cedars Sinai Medical Care Foundation
Los Angeles, CA

Jeffrey S. Weber, MD, PhD
Deputy Director
Laura and Isaac Perlmutter Cancer Center
Professor of Medicine
NYU Langone Medical Center
New York, NY